Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite reported Q2 ARR of $508M (+21%) and revenue of $131M (+16%), but missed the bottom end of guidance due to $4M of large transactions slipping and slower pricing/footprint uplift from Insights conversions (notably in U.S. state/local). Management lowered full-year 2026 ARR guidance to $550M–$560M (down $15M at the midpoint) and revenue guidance to $555M–$561M (+17%–18%), citing elongated sales cycles (~6 weeks) tied to new administrative/procurement requirements for cloud/AI and foreign-entity permitting, plus weaker-than-expected pricing uplift. Offsetting positives included Defense & Intelligence ARR growing 25% and a first major FedRAMP Guardian deal with a seven-figure initial order; shares are likely to react as the guidance cut outweighs the operational positives.

Analysis

The market should read this less as a demand collapse and more as a conversion-tax on a business moving upmarket. The problem is that cloud/AI and higher-acuity public-sector workflows bring more procurement checkpoints, which lengthens cash conversion and makes management’s forecast quality part of the valuation debate; that usually compresses multiples before it hurts the long-term model. The second-order winner is any domestic vendor that can clear procurement with less friction, especially U.S.-based public-safety software and evidence-management names where “foreign entity” risk is not a headline overhang.

The more important signal is mix: core retention looks sticky, but the incremental dollar from migration is fading, which means the install base is nearing saturation on the legacy uplift path. That shifts the burden onto newer products to create true net expansion rather than merely replacing old ARR at a better feature set. If Genesis/Guardian scale, this can still re-rate over 6-18 months; if not, CLBT becomes a high-quality but slower-growing govtech compounder with a premium multiple problem.

Near term, the key catalyst is operational proof, not product narrative: the next quarter should show whether the new permitting/process regime actually shortens cycle time or merely makes forecasting more conservative. A second miss would likely trigger another de-rating and force investors to question whether the foreign-filer issue is structural in Europe and U.S. federal, not transitory. The contrarian view is that the selloff may be overdone if the lost deals are truly deferred rather than lost, but that only matters if conversion and new-logo booking visibly reaccelerate within one to two quarters.

Key Decisions for Investors

• Avoid chasing CLBT on the initial drawdown; wait for one more quarter of evidence that procurement frictions are normalized. Falsifier: another guide cut or another 4-6 week slip in federal/EMEA close rates.
• Pair trade for the next 1-3 months: long AXON / short CLBT. Rationale: domestic procurement advantage and cleaner forecast quality versus a foreign-filer govtech name with elongated deal cycles; cover if CLBT reaccelerates net new ARR.
• For existing CLBT longs, buy 3-6 month put spreads into the next earnings date as a low-cost hedge against a second execution miss. Best risk/reward if shares rebound on relief without a hard re-acceleration in bookings.
• Watch PLTR as a relative beneficiary of public-sector cloud spending if CLBT’s procurement burden proves structural. A widening performance gap would confirm that compliance friction is becoming a share-shift, not just a timing issue.